Radiaction Receives FDA Clearance for its Radiation Protection System and Secures $10M

3 April, 2022

Mounted directly on the C-arm, Radiaction's Shield System blocks and captures the scattered radiation at the source. Proceeds will be used to launch Radiaction's Shield System in the US

Radiaction Medical, which has developed a device to protect medical staff from scattered radiation in interventional cardiology and electrophysiology sectors, announced FDA 510(K) clearance for the marketing of its Shield System in the US.

In addition, the company has completed a $10 million round of financing led by current investors, InnovaHealth Partners. Proceeds will be used to launch Radiaction’s Shield System in the US and to further commercialize in Europe.

Individuals working in catheterization laboratories (“cath labs”) are exposed to high levels of scattered radiation generated from the use of X-ray fluoroscopy. The medical teams wear heavy lead aprons for protection, but their heads, arms and legs are unprotected, leading to an increase in risk for brain tumors, cognitive degradation and other radiation-related illnesses. In addition, the heavy lead aprons can cause severe orthopedic injuries. A significant part of the radiation is scattered throughout the cath lab by its interaction with the patient’s body and X-ray table. Mounted directly on the C-arm, Radiaction’s Shield System blocks and captures the scattered radiation at the source. Clinical studies demonstrate that the device reduces radiation in the entire cath lab by over 90%, with even higher reduction rates to the head and upper body of all personnel in the room.

Jonathan Yifat, Radiaction’s CEO, said, “We are very pleased with the FDA clearance of our device and look forward to protecting the physicians and medical personnel performing interventional procedures in the US. This financing will drive our commercialization in the US and Europe, and allow us to build our team and market presence. We are excited to take this next step with our long-time partner, InnovaHealth Partners, who has tremendous experience backing the fast commercial growth of technology companies.”

Tested in a real-life clinical environments, Radiaction’ system demonstrated an entire room scattered radiation reduction performance of 91.2% in IC procedures and 93.3% in EP procedures. These rates are on par with the protection provided to the body’s core by lead aprons. Importantly, Radiaction is protecting heads, arms, long bones and feet which are outside of the lead apron and are exposed and subjected to harmful cumulative radiation damage. This clinical experience also demonstrated high physician satisfaction with the integration into the clinical workflow.

Radiaction was founded by Amir Belson, MD and its lead investor is InnovaHealth Partners, LP.

Share via Whatsapp

Posted in: Medical , News

Posted in tags: Radiaction